Medical Device | April 29, 2026
FDA okays AstraZeneca’s triple therapy Breztri for asthma
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
New home-use glucometer delivers results in under 10 seconds with simplified testing, large memory storage, and user-friendly design
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
Subscribe To Our Newsletter & Stay Updated
